注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Biomea Fusion Inc是一家處於臨床前階段的生物製藥公司。該公司專注於發現、開發和商業化不可逆轉的小分子藥物,用於治療基因定義的癌症患者。該公司已經建立了聚變系統發現平台,以推進不可逆轉的小分子候選產品管道。該公司的主要候選產品BMF-219是一種口服生物利用、有效和選擇性的不可逆美寧抑製劑,menin是一種重要的轉錄調節因子,已知在多種癌症的致癌信號傳導中發揮直接作用。該公司正在開發BMF-219,用於治療依賴menin的液體和固體腫瘤,包括含有混合譜系白血病(MLL)融合蛋白的白血病。該公司還正在推進其他臨床前不可逆項目,以治療某些癌症。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Ramses M. Erdtmann | 59 | 2017 | Co-Founder, President, COO & Director |
Thomas Andrew Butler | 41 | 2017 | Co-Founder, Chairman & CEO |
Michael J. M. Hitchcock | 73 | 2021 | Independent Director |
Sumita Ray | 49 | 2021 | Independent Director |
Eric M. Aguiar | 61 | 2020 | Independent Lead Director |
Bihua Chen | 55 | 2020 | Independent Director |
David D. Smith | 53 | 2022 | Member of Scientific Advisory Board |
Rohit Kulkarni | - | - | Member of Scientific Advisory Board |
Bruce H. Lipshutz | - | 2022 | Member of Scientific Advisory Board |
Jeremy Pettus | - | 2023 | Member of Scientific Advisory Board |
Elizabeth A. Faust | 58 | 2022 | Independent Director |
Xianxin Hua | - | 2022 | Member of Scientific Advisory Board |
Margaret A. Tempero | - | 2022 | Member of Scientific Advisory Board |
David B. Ball | - | 2022 | Member of Scientific Advisory Board |
Jeffrey Rubnitz | - | 2022 | Member of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核